Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18419406 | METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTS | January 2024 | July 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18497415 | SPATIAL TRANSCRIPTOMICS FOR ANTIGEN-RECEPTORS | October 2023 | July 2024 | Allow | 9 | 2 | 0 | No | No |
| 18336901 | METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTS | June 2023 | January 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18315289 | SPATIAL TRANSCRIPTOMICS FOR ANTIGEN-RECEPTORS | May 2023 | October 2023 | Allow | 5 | 1 | 0 | No | No |
| 18187578 | MOLECULE COUNTING OF METHYLATED CELL-FREE DNA FOR TREATMENT MONITORING | March 2023 | January 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18184615 | METHOD AND APPARATUS FOR RAPID ANALYSIS OF A BIOLOGICAL SAMPLE | March 2023 | February 2024 | Allow | 11 | 1 | 0 | No | No |
| 18148350 | NEXT-GENERATION SEQUENCING FOR PROTEIN MEASUREMENT | December 2022 | December 2023 | Allow | 12 | 1 | 0 | No | No |
| 17822115 | Varin Markers | August 2022 | October 2023 | Allow | 14 | 2 | 1 | Yes | No |
| 17857723 | COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE | July 2022 | February 2024 | Allow | 20 | 0 | 0 | No | No |
| 17699980 | METHOD FOR IDENTIFYING AND QUANTIFYING ORGANIC AND BIOCHEMICAL SUBSTANCES | March 2022 | October 2024 | Abandon | 30 | 1 | 0 | No | No |
| 17628385 | USE OF DETECTION REAGENT FOR DETECTING METHYLATION OF GENES ASSOCIATED WITH COLORECTAL CANCER, AND KIT | January 2022 | July 2023 | Allow | 18 | 2 | 1 | Yes | No |
| 17552135 | SPATIAL TRANSCRIPTOMICS FOR ANTIGEN-RECEPTORS | December 2021 | April 2023 | Allow | 16 | 2 | 0 | Yes | No |
| 17539019 | NANOSPLASH: A SALIVA-BASED DIAGNOSTIC FOR VIRAL INFECTION SUITABLE FOR HOME USE | November 2021 | August 2022 | Allow | 8 | 1 | 1 | No | No |
| 17535496 | DETERMINATION OF FETAL DNA FRACTION IN A SAMPLE | November 2021 | July 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17529896 | NUCLEIC ACID CONTROL MOLECULES FROM NON-HUMAN ORGANISMS | November 2021 | November 2023 | Allow | 24 | 0 | 0 | No | No |
| 17481622 | BIOMARKER IDENTIFICATION | September 2021 | June 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17412376 | SYSTEM AND METHOD FOR PREPARATION OF NUCLEOTIDE SOLUTIONS | August 2021 | January 2024 | Allow | 29 | 0 | 0 | No | No |
| 17445286 | Compositions and Methods for Analyzing Modified Nucleotides | August 2021 | June 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17400168 | DETECTION OF HYDROXYMETHYLCYTOSINE BASES | August 2021 | March 2024 | Allow | 31 | 2 | 1 | No | No |
| 17388410 | KITS FOR SINGLE-STEP ANALYTE DETECTION WITH PROCESS CONTROL | July 2021 | April 2024 | Allow | 32 | 2 | 0 | No | No |
| 17379918 | METHODS FOR EVALUATING TUMOR CELL SPHEROIDS USING 3D MICROFLUIDIC CELL CULTURE DEVICE | July 2021 | June 2024 | Allow | 35 | 2 | 0 | No | Yes |
| 17363282 | Resonator Networks for Improved Label Detection, Computation, Analyte Sensing, and Tunable Random Number Generation | June 2021 | December 2023 | Allow | 29 | 2 | 0 | Yes | No |
| 17363842 | Resonator Networks for Improved Label Detection, Computation, Analyte Sensing, and Tunable Random Number Generation | June 2021 | December 2023 | Allow | 29 | 2 | 0 | Yes | No |
| 17360014 | COLUMN-BASED DEVICE AND METHOD FOR RETRIEVAL OF RARE CELLS BASED ON SIZE, AND USES THEREOF | June 2021 | December 2023 | Allow | 30 | 1 | 1 | No | No |
| 17304452 | FLUIDICS SYSTEMS FOR SEQUENTIAL DELIVERY OF REAGENTS | June 2021 | December 2023 | Allow | 30 | 2 | 0 | No | No |
| 17333376 | Transcriptome In Vivo Analysis (TIVA) and Transcriptome In Situ Analysis (TISA) | May 2021 | August 2023 | Allow | 27 | 1 | 0 | No | No |
| 17333142 | SYSTEM AND METHOD FOR ISOLATING AND ANALYZING CELLS | May 2021 | January 2022 | Allow | 8 | 1 | 1 | Yes | No |
| 17211231 | ARRAY SYSTEM FOR IDENTIFYING AND LOCALIZING TARGET NUCLEIC ACIDS | March 2021 | May 2023 | Abandon | 25 | 4 | 0 | Yes | No |
| 17210202 | CORRECTING FOR DEAMINATION-INDUCED SEQUENCE ERRORS | March 2021 | June 2023 | Allow | 27 | 1 | 0 | No | No |
| 17208940 | METHODS OF EPIGENETIC ANALYSIS | March 2021 | March 2022 | Abandon | 11 | 1 | 0 | No | No |
| 17181351 | Compositions and Methods for Analyzing Modified Nucleotides | February 2021 | November 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 17161007 | CAPTURING OLIGONUCLEOTIDES IN SPATIAL TRANSCRIPTOMICS | January 2021 | July 2024 | Allow | 41 | 2 | 1 | Yes | No |
| 17148210 | HIGH THROUGHPUT DISCOVERY OF NEW GENES FROM COMPLEX MIXTURES OF ENVIRONMENTAL MICROBES | January 2021 | June 2023 | Allow | 29 | 1 | 0 | No | No |
| 17146163 | LYSIS BUFFERS FOR EXTRACTING NUCLEIC ACIDS | January 2021 | July 2023 | Allow | 30 | 1 | 0 | Yes | No |
| 17144971 | Spatially Encoded Biological Assays | January 2021 | March 2021 | Allow | 2 | 0 | 0 | No | No |
| 17257611 | A METHOD OF ctDNA LIBRARY CONSTRUCTION AND SEQUENCING DATA ANALYSIS FOR SIMULTANEOUSLY DETECTING MULTIPLE COMMON MUTATIONS IN LIVER CANCER | January 2021 | March 2024 | Allow | 39 | 2 | 1 | No | No |
| 16952566 | Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal Cancer | November 2020 | May 2023 | Allow | 30 | 1 | 0 | No | No |
| 16951758 | TREATING OR INHIBITING SEVERE SEPSIS BASED ON MEASURING DEFENSIN ALPHA 4 (DEFA4) EXPRESSION | November 2020 | March 2024 | Allow | 40 | 2 | 1 | No | No |
| 17097824 | Spatially Encoded Biological Assays | November 2020 | March 2021 | Allow | 4 | 1 | 0 | Yes | No |
| 17091435 | METHOD OF PARTIAL LYSIS AND ASSAY | November 2020 | March 2023 | Allow | 28 | 1 | 0 | Yes | No |
| 17085542 | DETECTING OVARIAN CANCER | October 2020 | February 2023 | Allow | 28 | 1 | 0 | No | No |
| 17039642 | COMPOSITIONS AND METHODS FOR ANALYZING CELL-FREE DNA IN METHYLATION PARTITIONING ASSAYS | September 2020 | October 2023 | Allow | 36 | 3 | 0 | Yes | Yes |
| 17037267 | NUCLEIC ACID METHYLATION ANALYSIS | September 2020 | July 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17029564 | CLASSIFIER FOR THE MOLECULAR CLASSIFICATION OF MULTIPLE MYELOMA | September 2020 | June 2022 | Abandon | 21 | 1 | 0 | No | No |
| 17040461 | Methods Involving Nucleic Acid Analysis of Milk | September 2020 | August 2023 | Allow | 35 | 3 | 0 | Yes | No |
| 17023442 | COMPOSITIONS AND METHODS FOR MAINTAINING SPLICING FIDELITY | September 2020 | July 2023 | Abandon | 34 | 1 | 1 | No | No |
| 17022597 | FRAGMENT SIZE CHARACTERIZATION OF CELL-FREE DNA MUTATIONS FROM CLONAL HEMATOPOIESIS | September 2020 | March 2024 | Allow | 42 | 3 | 1 | Yes | No |
| 17020516 | NUCLEIC ACID PRESERVATION SOLUTION AND METHODS OF MANUFACTURE AND USE | September 2020 | July 2022 | Allow | 22 | 2 | 0 | Yes | No |
| 17018692 | METHODS AND SYSTEMS FOR SCREENING FOR CONDITIONS | September 2020 | March 2024 | Allow | 42 | 3 | 1 | Yes | No |
| 17018347 | EXPRESSION AND GENETIC PROFILING FOR TREATMENT AND CLASSIFICATION OF DLBCL | September 2020 | April 2024 | Abandon | 43 | 4 | 1 | No | No |
| 17017045 | COMPOSITIONS AND METHODS FOR DIAGNOSING, EVALUATING AND TREATING CANCER BY MEANS OF THE DNA METHYLATION STATUS | September 2020 | July 2023 | Allow | 34 | 1 | 1 | Yes | No |
| 16978963 | PRODUCTS FOR ASSESSING COLORECTAL CANCER MOLECULAR SUBTYPE AND RISK OF RECURRENCE AND FOR DETERMINING AND ADMINISTERING TREATMENT PROTOCOLS BASED THEREON | September 2020 | August 2022 | Allow | 23 | 3 | 0 | Yes | No |
| 17011923 | Spatially Distinguished, Multiplex Nucleic Acid Analysis of Biological Specimens | September 2020 | August 2023 | Abandon | 35 | 2 | 0 | Yes | No |
| 16977197 | A METHOD OF DETERMINING A RISK OF CANCER | September 2020 | January 2024 | Allow | 41 | 4 | 1 | Yes | No |
| 16968811 | METHOD OF PREDICTING RESPONSE TO THERAPY BY ASSESSING TUMOR GENETIC HETEROGENEITY | August 2020 | April 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 16967497 | REPEAT RNA AS BIOMARKERS OF TUMOR IMMUNE RESPONSE | August 2020 | March 2023 | Abandon | 32 | 2 | 1 | No | No |
| 16940486 | NANOSTRUCTURES TO CONTROL DNA STRAND ORIENTATION AND POSITION LOCATION FOR TRANSVERSE DNA SEQUENCING | July 2020 | March 2022 | Allow | 20 | 1 | 1 | Yes | No |
| 16935447 | METHODS FOR DETERMINING BASE LOCATIONS IN A POLYNUCLEOTIDE | July 2020 | May 2022 | Abandon | 22 | 1 | 0 | No | No |
| 16961245 | Composition and Method for Concentration and Enrichment of Nucleic Acids | July 2020 | April 2022 | Allow | 21 | 1 | 0 | No | No |
| 16912597 | METHODS FOR IDENTIFYING CARRIER STATUS AND ASSESSING RISK FOR SPINAL MUSCULAR ATROPHY | June 2020 | May 2022 | Abandon | 23 | 1 | 0 | No | No |
| 16909366 | Method for obtaining single-cell mRNA sequence | June 2020 | May 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 16908056 | DETECTING GASTROINTESTINAL NEOPLASMS | June 2020 | March 2022 | Allow | 20 | 1 | 0 | No | No |
| 15733262 | MULTIPLEX 5MC MARKER BARCODE COUNTING FOR METHYLATION DETECTION IN CELL FREE DNA | June 2020 | April 2023 | Abandon | 34 | 2 | 1 | Yes | No |
| 16946297 | COMPOSITIONS AND METHODS FOR UNIDIRECTIONAL NUCLEIC ACID SEQUENCING | June 2020 | August 2023 | Abandon | 38 | 1 | 1 | No | No |
| 16894526 | METHODS AND COMPOSITIONS FOR LABELING CELLS | June 2020 | June 2022 | Abandon | 25 | 1 | 0 | No | No |
| 16877429 | METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA AND THE USE OF BIOMARKERS AS A PREDICTOR TO RESPONSIVENESS TO DRUGS | May 2020 | May 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16866252 | CORRECTING FOR DEAMINATION-INDUCED SEQUENCE ERRORS | May 2020 | March 2021 | Allow | 10 | 2 | 0 | No | No |
| 16758644 | DIAGNOSIS AND/OR PROGNOSIS OF HER2-DEPENDENT CANCER USING MOESIN AS A BIOMARKER | April 2020 | June 2023 | Abandon | 37 | 1 | 1 | No | No |
| 16855177 | METHODS AND SYSTEMS FOR SAMPLE PREPARATION AND ANALYSIS | April 2020 | October 2022 | Allow | 30 | 1 | 0 | Yes | No |
| 16840314 | DNA LIGATION ON RNA TEMPLATE | April 2020 | June 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16649281 | TELOMERE-CONTROLLING GENE FAMILY DISCOVERED IN MOUSE THYMUS LYMPHOMA CELL IRRADIATED WITH LOW-DOSE RATE LOW-LEVEL RADIATION, AND METHOD FOR DETECTING SAME | March 2020 | May 2023 | Abandon | 38 | 2 | 0 | Yes | No |
| 16819564 | Microarray Based Multiplex Pathogen Analysis for Plants, Agriculture, Food, and Water | March 2020 | July 2023 | Allow | 40 | 2 | 1 | No | No |
| 16814908 | SYSTEMS AND METHODS FOR PROCESSING OPTICALLY TAGGED BEADS | March 2020 | November 2023 | Allow | 44 | 3 | 0 | Yes | No |
| 16645749 | METHOD FOR METHYLATION ANALYSIS | March 2020 | October 2021 | Abandon | 19 | 0 | 1 | No | No |
| 16643197 | METHOD TO CONFIRM VARIANTS IN NGS PANEL TESTING BY SNP GENOTYPING | February 2020 | February 2024 | Abandon | 47 | 4 | 1 | Yes | No |
| 16642430 | Clear Cell Renal Cell Carcinoma Biomarkers | February 2020 | November 2022 | Abandon | 33 | 1 | 1 | Yes | No |
| 16799559 | DNA METHYLATION BIOMARKERS FOR BLADDER CANCER | February 2020 | October 2022 | Allow | 32 | 1 | 1 | Yes | No |
| 16796034 | BRUSH POLYMER-ASSISTED COMPACTION OF OLIGONUCLEOTIDES | February 2020 | May 2021 | Allow | 15 | 1 | 1 | Yes | No |
| 16795968 | Methods And Compositions For Templated Assembly Of Nucleic Acid Specific Heterocompounds | February 2020 | March 2024 | Abandon | 49 | 3 | 1 | No | No |
| 16796026 | MATERIALS AND METHODS FOR ASSESSING PROGRESSION OF PROSTATE CANCER | February 2020 | July 2022 | Abandon | 29 | 0 | 1 | No | No |
| 16792051 | NANO46 GENES AND METHODS TO PREDICT BREAST CANCER OUTCOME | February 2020 | May 2022 | Abandon | 27 | 1 | 0 | No | No |
| 16789122 | METHODS FOR DETECTING HEAD AND NECK CANCER | February 2020 | July 2023 | Abandon | 41 | 1 | 1 | No | No |
| 16638482 | NOVEL BIOMARKERS FOR CANCER DIAGNOSIS, PREDICTION OR STAGING | February 2020 | July 2023 | Allow | 41 | 3 | 0 | Yes | No |
| 16745539 | NANOFLUIDIC DEVICES FOR THE RAPID MAPPING OF WHOLE GENOMES AND RELATED SYSTEMS AND METHODS OF ANALYSIS | January 2020 | February 2022 | Allow | 25 | 1 | 1 | No | No |
| 16631570 | BIOMARKERS FOR INTRACRANIAL ANEURYSM | January 2020 | February 2023 | Allow | 37 | 2 | 1 | Yes | No |
| 16631370 | DDX24 MUTATIONS AND USE THEREOF | January 2020 | March 2023 | Abandon | 38 | 2 | 1 | No | No |
| 16631145 | Novel Methods of Predicting Transplant Rejection Risk | January 2020 | March 2023 | Allow | 38 | 1 | 1 | No | No |
| 16741665 | DETECTION OF TARGET NUCLEIC ACIDS USING HYBRIDIZATION | January 2020 | August 2021 | Allow | 19 | 2 | 0 | Yes | No |
| 16630299 | CANCER DETECTION AND CLASSIFICATION USING METHYLOME ANALYSIS | January 2020 | February 2024 | Allow | 49 | 4 | 0 | Yes | No |
| 16629520 | METHOD OF DIAGNOSIS OF COLORECTAL CANCER | January 2020 | August 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16623870 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR PARKINSON'S DISEASE PROGNOSIS | December 2019 | April 2023 | Allow | 40 | 3 | 1 | No | No |
| 16713571 | ENZYMATIC METHODS FOR GENOTYPING ON ARRAYS | December 2019 | September 2022 | Allow | 33 | 2 | 0 | Yes | No |
| 16702331 | CARTRIDGE FOR THE DETECTION OF METHYLATED DNA | December 2019 | January 2023 | Allow | 38 | 3 | 0 | Yes | No |
| 16617756 | DNA-GLYCAN CONJUGATES AND METHODS OF USE | November 2019 | August 2023 | Allow | 45 | 2 | 1 | Yes | No |
| 16696604 | METHOD FOR IDENTIFYING AND QUANTIFYING ORGANIC AND BIOCHEMICAL SUBSTANCES | November 2019 | November 2022 | Abandon | 36 | 2 | 0 | No | No |
| 16691247 | METHODS OF DNA EPIGENETIC ANALYSIS | November 2019 | December 2021 | Abandon | 25 | 3 | 0 | Yes | No |
| 16691255 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | November 2019 | November 2021 | Abandon | 24 | 1 | 1 | No | No |
| 16686613 | Method and Device for Encapsulating Cell in Liquid Droplet for Single-Cell Analysis | November 2019 | April 2023 | Abandon | 41 | 2 | 1 | Yes | No |
| 16687672 | FLUIDICS SYSTEM FOR SEQUENTIAL DELIVERY OF REAGENTS | November 2019 | March 2021 | Allow | 16 | 1 | 0 | Yes | No |
| 16685334 | NEEDLE-BASED DEVICES AND METHODS FOR IN VIVO DIAGNOSTICS OF DISEASE CONDITIONS | November 2019 | February 2023 | Allow | 39 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAUNER, JOSEPH G.
With a 60.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 24.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DAUNER, JOSEPH G works in Art Unit 1634 and has examined 648 patent applications in our dataset. With an allowance rate of 51.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner DAUNER, JOSEPH G's allowance rate of 51.4% places them in the 8% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DAUNER, JOSEPH G receive 2.21 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by DAUNER, JOSEPH G is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +41.1% benefit to allowance rate for applications examined by DAUNER, JOSEPH G. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 20.3% of applications are subsequently allowed. This success rate is in the 14% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 35.9% of cases where such amendments are filed. This entry rate is in the 46% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 68% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 79.2% of appeals filed. This is in the 67% percentile among all examiners. Of these withdrawals, 63.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 71.4% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.0% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.